-
Dimdazenil Capsules Approved for Marketing by China NMPA
2023-11-29
Recently, the Category 1 innovative drug Dimdazenil Capsules of Zhejiang Jingxin Pharmaceutical Co., Ltd. was approved for marketing by China NMPA. This drug is indicated for short-term treatment for insomnia patients.
-
Atilotrelvir Tablets/Ritonavir Tablets Approved with Conditions
2023-11-24
Recently, the Category 1 innovative drug Atilotrelvir Tablets/Ritonavir Tablets (co-packaged) (Chinese trade name: 泰中定) of Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. was approved with conditions by China NMPA through the emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Children's Chiqiao Qingre Syrup Approved for Marketing
2023-11-17
Recently, the Category 2.2 moidfied new traditional Chinese medicine Children's Chiqiao Qingre Syrup of Jumpcan Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. It is a pediatric drug with highly increased compliance after the modification of dosage form.
-
Vebreltinib Enteric Capsules Approved with Conditions for Marketing
2023-11-16
Recently, the Category 1 innovative drug Vebreltinib Enteric Capsules of Beijing Pearl Biotechnology Limited Liability Company was approved for marketing with conditions by China NMPA.
-
Xianglei Tangzu Cream Approved with Conditions for Marketing
2023-11-14
Recently, the natural products Category 1.1 innovative drug Xianglei Tangzu Cream (Fespixon Cream) of Oneness Biotech Co., Ltd. was approved for marketing with conditions by China NMPA.
-
Glofitamab Injection Approved with Conditions for Marketing
2023-11-08
Recently, the Glofitamab Injection (trade name: 高罗华/Columvi) of Roche Pharma (Schweiz) AG is approved with conditions by China NMPA.
